Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyBlue Cross MA PAE Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MassachusettsPolicy 235

    Prostate Artery Embolization for Benign Prostatic Hyperplasia

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 235 alerts

    Get alerted when Policy 235 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for prostate artery embolization used to treat benign prostatic hyperplasia for Commercial and Medicare Advantage members; the service is investigational and not covered.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyProstate Artery Embolization for Benign Prostatic Hyperplasia
    Policy CodePolicy 235
    Change TypeNew policycoding clarified
    Effective DateJune 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateNot specified
    Key ActionObtain precertification or preauthorization when a service described in this policy is performed inpatient.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    InvestigationalCoverage status of PAE for BPH
    InsufficientEvidence conclusion
    7 RCTsRandomized controlled trials
    31Supporting references

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Prostate artery embolization (PAE) used as a treatment for benign prostatic hyperplasia (BPH) is considered investigational.

    Coding Information

    Experimental CPT CodesCPTExperimental
    37242Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquired arterial malformations, arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms).
    Experimental HCPCS CodesHCPCSExperimental
    C9797Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction performed in the non-facility setting.

    Provider Actions and Coverage Status

    Prior Authorization

    Inpatient Prior Authorization Required

    Precertification or preauthorization is required for all products when a service described in this policy is performed on an inpatient basis.

    Denial Risk

    Investigational / Non-Covered Service

    Prostate artery embolization (PAE) for benign prostatic hyperplasia is considered investigational and is not a covered service for applicable Commercial and Medicare Advantage members.

    • Applies to Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM members.
    • For outpatient procedures, PAE for BPH is not a covered service for the products listed above.
    • Code inclusion or exclusion does not determine coverage or provider reimbursement; verify the member’s contract benefits and report services with current industry-standard codes and applicable modifiers.

    Background

    Benign prostatic hyperplasia (BPH) is a histologic enlargement of stromal and glandular epithelial cells in the prostate transition zone. It may result in prostate enlargement, bladder outlet obstruction, and lower urinary tract symptoms such as urinary frequency, urgency, weak stream, straining, and nocturia. Prostate artery embolization (PAE) is a minimally invasive endovascular procedure in which microspheres are delivered through a catheter to reduce blood flow to multiple areas of the prostate. PAE has been studied as an alternative to transurethral resection of the prostate (TURP), the traditional standard treatment for BPH; however, the policy concludes that evidence is insufficient to establish improvement in net health outcome.

    Definitions

    Benign prostatic hyperplasia (BPH)
    DefinitionA histologic diagnosis defined by an increase in the total number of stromal and glandular epithelial cells within the transition zone of the prostate gland.
    Possible effectsIn some men, BPH results in prostate enlargement, which can lead to benign prostate obstruction and bladder outlet obstruction.
    Associated symptomsBPH-related obstruction is often associated with lower urinary tract symptoms, including urinary frequency, urgency, irregular flow, weak stream, straining, and waking at night to urinate.
    Prostate artery embolization (PAE)
    DefinitionA minimally invasive endovascular treatment that reduces blood supply to the prostatic arteries.
    TechniqueAn interventional radiologist injects microspheres through a catheter into blood vessels around the prostate, reducing blood supply to multiple areas.
    Treatment approachPAE uses an endovascular, embolic approach rather than a transurethral surgical approach; no surgical intervention is required.
    RecoveryRecovery times are often shorter than those associated with transurethral resection of the prostate (TURP).
    Lower urinary tract symptoms (LUTS)
    DefinitionLower urinary tract symptoms associated with benign prostatic hyperplasia.
    Storage symptomsUrinary frequency and urgency.
    Voiding symptomsIrregular flow, weak stream, and straining.
    Nocturnal symptomWaking at night to urinate.
    Transurethral resection of the prostate (TURP)
    Role in BPH treatmentThe traditional standard treatment for benign prostatic hyperplasia.
    Use as comparatorThe reference standard used for comparisons of benign prostatic hyperplasia procedures.
    Comparison with PAEPAE has been investigated as a minimally invasive alternative to TURP for men with lower urinary tract symptoms due to BPH.
    Evidence contextComparative studies have assessed symptoms, quality of life, urinary flow, prostate volume reduction, complications, and retreatment rates for PAE versus TURP.
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyProstate Artery Embolization for Benign Prostatic Hyperplasia
    Policy CodePolicy 235
    Change TypeNew policycoding clarified
    Effective DateJune 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateNot specified
    Key ActionObtain precertification or preauthorization when a service described in this policy is performed inpatient.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Actions and Coverage StatusBackgroundDefinitions